In a nationwide cohort of 35,762 Taiwanese diabetes patients followed for up to 5 years, GLP-1 receptor agonist treatment was associated with a 15% lower risk of developing knee osteoarthritis and a 9% lower risk of needing total knee replacement.
4.66% vs 8.81% developed knee osteoarthritisDiabetes patients taking GLP-1 receptor agonists had roughly half the rate of developing knee osteoarthritis over 5 years compared to propensity-matched non-users
What the researchers found
Among 1,976 propensity-matched T2DM patients (988 GLP-1RA users, 988 non-users) without baseline KOA, GLP-1RA treatment was associated with significantly lower KOA risk: 4.66% vs 8.81% developed KOA (adjusted HR = 0.852, 95% CI 0.784-0.930, P < 0.001).
Among 744 propensity-matched T2DM patients with existing KOA (372 GLP-1RA users, 372 non-users), GLP-1RA treatment was associated with lower total knee replacement rates: 10.48% vs 18.82% underwent TKR (adjusted HR = 0.913, 95% CI 0.885-0.977, P = 0.015). Kaplan-Meier survival analysis confirmed significantly different cumulative risk curves for both outcomes (log-rank P < 0.001 for both).
Why it matters
Knee osteoarthritis is the most common joint disease, affecting over 250 million people worldwide. Total knee replacement — while effective — is a major surgery with significant cost, recovery time, and complication risk. If GLP-1 drugs can reduce both KOA development and the need for TKR, this represents a substantial additional benefit for the hundreds of millions of T2DM patients worldwide. The effect may be mediated through weight loss (reducing mechanical joint stress), anti-inflammatory properties, or emerging evidence that GLP-1 receptors are expressed in cartilage and may directly protect joint tissue.
How the study worked
Population-based retrospective cohort study using Taiwan's National Health Insurance Database. 35,762 patients with T2DM were identified. GLP-1RA users were propensity score-matched 1:1 with non-users by sex, age, and inclusion date. Two analyses were performed: KOA development in T2DM without baseline KOA, and TKR rates in T2DM with baseline KOA. Cox proportional hazards regression estimated adjusted hazard ratios over a maximum 5-year follow-up.
What this study cannot tell us
As a retrospective observational study, it cannot establish causation — GLP-1RA users may differ from non-users in unmeasured ways despite propensity score matching. The study could not determine whether the benefit was driven by weight loss (the most likely explanation), anti-inflammatory effects, or direct joint-protective mechanisms. Specific GLP-1RA agents and doses were not differentiated. The Taiwanese population may have different obesity and OA patterns than other populations. The ICD-based diagnosis of KOA may lack precision compared to imaging or clinical assessment.
How to read the evidence
This is a large population-based retrospective cohort study with propensity score matching, representing moderately strong observational evidence. The large sample size (35,762 patients) and nationwide database provide robust statistical power, but the observational design cannot establish causation.
When this study was published
Published in 2025, this is a very recent study reflecting the growing interest in GLP-1 drugs' benefits beyond glycemic control, including potential joint-protective effects.
The bigger picture
This study adds joint protection to the growing list of GLP-1 drug benefits beyond glucose control — joining cardiovascular protection, kidney protection, liver disease improvement, and potential neurological benefits. The finding is particularly significant because it suggests GLP-1 drugs could reduce the burden of one of the most common and costly surgical procedures worldwide (over 1 million knee replacements annually in the US alone). It contributes to the emerging narrative that GLP-1 drugs may be among the most broadly beneficial medications ever developed.
Questions still open
- Is the reduced KOA risk primarily due to weight loss from GLP-1 therapy, or do GLP-1 drugs have direct anti-inflammatory or chondroprotective effects?
- Would GLP-1 receptor agonists benefit non-diabetic patients with obesity-related knee osteoarthritis?
- Should GLP-1 drugs be considered earlier in T2DM management specifically to prevent osteoarthritis in at-risk patients?
Common questions
Can GLP-1 drugs like Ozempic prevent knee arthritis?
Would GLP-1 drugs help with knee arthritis if I don't have diabetes?
Read the original research
Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.
Medicine, 104(6), e41243
Citation
Lin, Chih-Ping; Chung, Chi-Hsiang; Lu, Chieh-Hua; Su, Sheng-Chiang; Kuo, Feng-Chih; Liu, Jhih-Syuan; Li, Peng-Fei; Huang, Chia-Luen; Ho, Li-Ju; Chen, Kuan-Chan; Chang, Chun-Yung; Lin, Ming-Shiun; Liu, Yi-Chen; Cheng, An-Che; Lin, Hong-Han; Kuo, Shi-Wen; Lee, Chien-Hsing; Hsieh, Chang-Hsun; Hung, Yi-Jen; Liu, Hsin-Ya; Guo, Lan-Yuen; Chien, Wu-Chien. (2025). Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.. Medicine, 104(6), e41243. https://doi.org/10.1097/MD.0000000000041243